Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DM9QF65)

Drug Name	GR-MD-02 DM9QF65
Synonyms	Belapectin
Drug Type	Protein

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

3 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Melanoma	DIS1RRCY	2C30	Phase 2	[1]
Hypertension	DISLL965	BA00-BA04	Phase 2	[2]
Plaque psoriasis	DISQX1LF	EA90.0	Phase 2	[3]
------------------------------------------------------------------------------------

1 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Non-alcoholic steatohepatitis	DIST4788	DB92.1	Phase 1	[4]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02421094) Clinical Study for Non-Invasive Imaging Methods for GR-MD-02 for Treatment of Liver Fibrosis. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT02462967) Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis (NASH-CX). U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	ClinicalTrials.gov (NCT01899859) Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis. U.S. National Institutes of Health.